DUBLIN and MYSTIC, Conn., May 12 Amarin Corporation plc (Nasdaq: AMRN) has scheduled a conference call for Thursday, May 13, 2010 at 4:00 p.m. GMT (11:00 a.m. Eastern Time) to discuss selected financial results and provided a progress update of the Company's ANCHOR and MARINE trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.
The conference call may be heard live via the investor relations section of the Company's website at www.amarincorp.com and will also be available by dialing the following numbers:
Replay is available will be made available for a period of two weeks following the conference calls. To hear a replay of the call dial 1-201-612-7415 (outside U.S.) 1-877-660-6853 (inside U.S.). For both dial in numbers please use account number is 286 and conference id 350729.
Amarin is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), has commenced enrolment of patients in two pivotal Phase 3 clinical trials for the treatment of patients with very high triglyceride levels and for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials were designed under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.
From outside U.S. dial-in: (201) 689-8565 From inside U.S. dial-in: (877) 407-0778
SOURCE Amarin Corporation plc